News and events
News
Our articles in News are shown below.
-
Towards the ‘holy grail’ of anticoagulant drugs
New Cambridge spin-out raises $11 million in funding to develop revolutionary new drug for thrombosis, which causes heart attacks and strokes.
-
Clearing the BAR to oral vaccines
A new technology under development by an academic–industry partnership protects oral vaccines from destruction by the digestive system.
-
Democratising design
A new simulator could help the elderly or disabled users engage more effectively with electronic devices, including websites, smartphones and digital television.
-
Sphere Fluidics wins award for academic spin-outs
University of Cambridge spin-out Sphere Fluidics was among the winners at the ACES awards – the only pan-European awards for academic spin-outs – held earlier this week in Brussels.
-
Flexible opals
A synthetic material which mimics the brightest and most vivid colours in nature, and changes colour when twisted or stretched, has been developed by researchers at the University of Cambridge, and could have important applications in the security, textile and sensing industries.
-
UCL and Cambridge share in £50m of new funding to help stimulate UK economy
University College London (UCL) and Cambridge have been awarded a share of a government investment of £50m into UK’s leading universities to drive growth, the Minister for Universities and Science has announced.
-
‘Mid-sized’ firms key to UK manufacturing
A new report suggests that global production shift to Asia may have “run its course” and points to “undervalued” mid-sized manufacturing firms as essential to UK economic regrowth.
-
New device could make diagnosing disease as simple as breathing
A range of diseases and conditions, from asthma to liver disease, could be diagnosed and monitored quickly and painlessly just by breathing, using gas sensing technology developed by a Cambridge spin-out.
-
Horizon Discovery announces collaboration with AstraZeneca
Cambridge Enterprise portfolio company Horizon Discovery and AstraZeneca have entered into an exclusive collaboration and licence agreement to explore Horizon’s first-in-class kinase target programme, HD-001, as a means of developing novel therapies for multiple cancer types.
-
Fighting online banking fraud
A security solution which protects against the most serious threat to online banking customers, responsible for millions in annual losses, is being rolled out across Europe by a Cambridge spin-out.